생화학분자생물학회

	Name: Sang Bum Kim ( sbk@syu.ac.kr )
	2021-present	Assistant Professor, Sahmyook University, Seoul
	2017-2021	Postdoctoral Researcher, Biocon, Seoul National university
	2010-2017	Ph.D., Department of molecular medicine and biopharmaceutical sciences, Graduate school of convergence science and technology, Seoul National University
	2008-2010	M.S, College of Pharmacy, Seoul National University

Plant-Derived Extracellular Vesicles as Nanocarriers for Combination Therapy in Breast Cancer: Enhancing Paclitaxel-Based Regimens

Breast cancer continues to be a leading cause of morbidity and mortality globally, with triple-negative breast cancer (TNBC) posing distinct challenges due to its aggressive nature and limited treatment options. Paclitaxel-based chemotherapy is commonly employed in breast cancer management, but its efficacy is often hindered by toxicity, multidrug resistance, and a lack of targeted delivery mechanisms. Addressing these obstacles, recent research has focused on extracellular vesicles (EVs), particularly plant-derived EVs, as innovative drug delivery systems with the potential to enhance therapeutic effectiveness while minimizing side effects. Plant-derived EVs present notable advantages, including biocompatibility, low immunogenicity, cost-effectiveness, and scalability, making them a promising natural platform for delivering chemotherapeutics such as paclitaxel and doxorubicin directly to tumor cells. This review first examines the therapeutic potential of drug combination therapy via EVs in breast cancer treatment, with an emphasis on TNBC, analyzing their capacity to enhance drug efficacy, overcome drug resistance, and selectively target cancer cells. Additionally, studies on EVs derived from plants like grapefruit, ginger, and tea leaves underscore their effectiveness in delivering chemotherapeutic agents while reducing side effects commonly associated with traditional delivery methods. Although plant-derived EVs are still in the early stages of investigation, current findings suggest that these nanocarriers could become transformative tools in oncology, providing a versatile and efficient platform for cancer treatment.


BMB Rep. 2025 Feb;58(2):53-63
https://pubmed.ncbi.nlm.nih.gov/39978779/